Patient derived xenografts generated from LKB1-deficient lung cancer patients displayed increased tumor necrosis with an impaired ability to adapt to metabolic stress mediated by the anti-angiogenic vascular endothelial growth factor (VEGF) inhibitor bevacizumab.206. Here, VEGFA is linked to neoplasm.